Phase 1 Dosing Underway for Nexalis’ IRX-616a with Final Participant Due June 2026
Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.
- Phase 1 trial dosing commenced for IRX-616a
- First-in-human study targeting panic disorder
- Safety Review Committee to assess dose escalation in April
- Trial on track to complete dosing by June 2026
- Plans to start Phase 2 study following Phase 1 completion
Trial Launch Marks a Milestone
Australian clinical-stage company Nexalis Therapeutics has taken a significant step forward by commencing dosing in its Phase 1 clinical trial of IRX-616a, a cannabidiol-based inhalation aerosol designed to treat panic disorder. This first-in-human study is a critical milestone in the company’s efforts to develop rapid-onset therapies for acute mental health conditions.
Understanding IRX-616a and Its Potential
IRX-616a is delivered via a pressurised metered-dose inhaler, providing a 2.5 mg dose of cannabidiol (CBD) per actuation. The inhalation route is intended to enable fast systemic absorption by bypassing the liver’s first-pass metabolism, potentially offering rapid relief for patients experiencing panic attacks. Panic disorder is a debilitating condition characterised by sudden, unexpected panic episodes and ongoing anxiety about future attacks, often severely impacting daily functioning.
Trial Design and Safety Oversight
The Phase 1 trial is a randomised, double-blind, placebo-controlled, single ascending dose study involving up to 24 healthy volunteers across three dose cohorts. The trial is being conducted at CMAX in Adelaide, a specialist early-phase clinical research unit. An independent Safety Review Committee (SRC) will oversee dose escalation decisions, with a scheduled meeting in early April to review emerging safety data and determine if the trial can progress to higher doses.
Looking Ahead to Phase 2
Nexalis Therapeutics plans to complete dosing of the final participant by June 2026. Following successful Phase 1 results, the company intends to initiate a Phase 2 study in patients diagnosed with panic disorder. This progression will be crucial in assessing the drug’s efficacy and further safety in the target population, moving closer to potential regulatory approval and market entry.
Strategic Positioning and Market Opportunity
The development of IRX-616a fits within Nexalis Therapeutics’ broader strategy to address unmet needs in mental health and pain management through rapid onset therapies. By focusing on acute conditions such as panic disorder, the company aims to fill gaps where current treatments may be inadequate or carry dependency risks. The use of cannabidiol and inhalation delivery could offer a novel approach with a favourable safety and onset profile.
Bottom Line?
As Nexalis advances IRX-616a through early trials, the coming months will be pivotal in defining its potential to transform panic disorder treatment.
Questions in the middle?
- Will the Safety Review Committee approve dose escalation in April?
- How will IRX-616a’s safety and tolerability profile compare to existing panic disorder treatments?
- What timeline and design will the planned Phase 2 trial follow after Phase 1 completion?
